Effect of diltiazem on histamine- and carbachol-induced bronchospasm in normal and asthmatic subjects.
Recently, several transmembrane calcium-channel blockers have been used in experimental models to investigate the mechanisms through which Ca++ ions contribute to the regulation of the contractile response of airway smooth muscle and to determine the therapeutic use of these drugs in bronchial asthma. Since the data from these studies are inconsistent and inconclusive, we studied the effect of diltiazem, a calcium-channel blocker previously not examined to our knowledge, on histamine- and carbachol-induced bronchoconstriction in healthy and in asymptomatic allergic bronchial asthma. The study was performed in a double-blind, randomized, placebo-controlled fashion, using a single oral dose of 60 mg of diltiazem. Airway reactivity to histamine and carbachol expressed by PD35SGaw was significantly but weakly attenuated by diltiazem in the asthmatic, but not in the normal subjects. Baseline lung function was not significantly influenced by diltiazem. We concluded that the effect of diltiazem on unspecific airway hyperresponsiveness in asthmatic subjects is too weak to justify a recommendation as therapy.
D000328:Adult; D001249:Asthma / Q000188:drug therapy*; D001552:Benzazepines / Q000627:therapeutic use*; D001986:Bronchial Spasm / Q000139:chemically induced / Q000188:drug therapy*; D002118:Calcium / Q000627:therapeutic use; D002217:Carbachol; D002986:Clinical Trials as Topic; D004110:Diltiazem / Q000627:therapeutic use*; D004311:Double-Blind Method; D006632:Histamine; D006801:Humans; D010919:Placebos; D011897:Random Allocation
D001552:Benzazepines; D010919:Placebos; D006632:Histamine; D002217:Carbachol; D004110:Diltiazem; D002118:Calcium